- Home
- PHAT vs IMTX Comparison
PHAT vs IMTX Comparison
Compare PHAT & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- IMTX
- Stock Information
- Founded
- PHAT 2018
- IMTX N/A
- Country
- PHAT United States
- IMTX Germany
- Employees
- PHAT N/A
- IMTX N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PHAT Health Care
- IMTX Health Care
- Exchange
- PHAT Nasdaq
- IMTX Nasdaq
- Market Cap
- PHAT 716.5M
- IMTX 653.9M
- IPO Year
- PHAT 2019
- IMTX N/A
- Fundamental
- Price
- PHAT $11.91
- IMTX $5.69
- Analyst Decision
- PHAT Strong Buy
- IMTX Strong Buy
- Analyst Count
- PHAT 5
- IMTX 4
- Target Price
- PHAT $16.40
- IMTX $14.67
- AVG Volume (30 Days)
- PHAT 1.1M
- IMTX 572.9K
- Earning Date
- PHAT 08-07-2025
- IMTX 08-13-2025
- Dividend Yield
- PHAT N/A
- IMTX N/A
- EPS Growth
- PHAT N/A
- IMTX N/A
- EPS
- PHAT N/A
- IMTX N/A
- Revenue
- PHAT $114,039,000.00
- IMTX $152,823,253.00
- Revenue This Year
- PHAT $194.40
- IMTX N/A
- Revenue Next Year
- PHAT $103.23
- IMTX $1.92
- P/E Ratio
- PHAT N/A
- IMTX N/A
- Revenue Growth
- PHAT 1049.82
- IMTX 83.61
- 52 Week Low
- PHAT $2.21
- IMTX $3.30
- 52 Week High
- PHAT $19.71
- IMTX $13.09
- Technical
- Relative Strength Index (RSI)
- PHAT 75.25
- IMTX 41.21
- Support Level
- PHAT $9.82
- IMTX $5.42
- Resistance Level
- PHAT $11.19
- IMTX $6.47
- Average True Range (ATR)
- PHAT 0.71
- IMTX 0.36
- MACD
- PHAT 0.17
- IMTX -0.11
- Stochastic Oscillator
- PHAT 94.07
- IMTX 21.77
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.